IBIO — iBio, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on IBIO
| date | signal | measured base rate |
|---|---|---|
| 2026-07-01 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-06-26 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-27 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
| 2026-03-26 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-03-26 | Banjak Marc Chief Legal Officer | Open-market purchase | 12.5K | 1.64 | 20.5K |
| 2026-03-26 | Banjak Marc Chief Legal Officer | Open-market purchase | 1.4K | 1.76 | 2.5K |
| 2026-03-19 | Duran Felipe Chief Financial Officer | Open-market purchase | 24.8K | 2.02 | 50.2K |
| 2026-03-19 | Brenner Martin See Remarks | Open-market purchase | 12.3K | 2.02 | 24.9K |
| 2025-01-10 | Parada Antonio Bernardino Guimaraes Director | Open-market purchase | 183.8K | 2.72 | 500.0K |
| 2025-01-10 | Arkowitz David Director | Open-market purchase | 18.4K | 2.72 | 50.0K |
| 2025-01-10 | Sender Gary Director | Open-market purchase | 9.2K | 2.72 | 25.0K |
| 2025-01-10 | Banjak Marc Chief Legal Officer | Open-market purchase | 9.2K | 2.72 | 25.0K |
| 2025-01-10 | Duran Felipe Chief Financial Officer | Open-market purchase | 9.2K | 2.72 | 25.0K |
| 2025-01-10 | Brenner Martin See Remarks | Open-market purchase | 9.2K | 2.72 | 25.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Affinity Asset Advisors, LLC | 5.9M | 3.1M |
| Frazier Life Sciences Management, L.P. | 3.7M | 2.0M |
| EcoR1 Capital, LLC | 3.0M | 1.6M |
| MILLENNIUM MANAGEMENT LLC | 2.9M | 1.5M |
| Logos Global Management LP | 2.5M | 1.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | 1.1M |
| Balyasny Asset Management L.P. | 1.9M | 1.0M |
| Ikarian Capital, LLC | 1.8M | 957.1K |
| CITADEL ADVISORS LLC | 1.8M | 956.4K |
| Sio Capital Management, LLC | 1.7M | 904.3K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about IBIO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →